2013 Fiscal Year Final Research Report
Development of a novel antidiabetic drug based on the targeting of GnT-IVa glycosyltransferase
| Project/Area Number |
23790363
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Kumamoto University (2013)
Osaka University (2011-2012) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KOREKANE Hiroaki 独立行政法人理化学研究所, 疾患糖鎖研究チーム, 研究員 (50421912)
NAKAJIMA Kazuki 独立行政法人理化学研究所, 神経膜機能研究チーム, 研究員 (10442998)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 糖鎖修飾 / グルコーストランスポーター / グルコースセンサー機能 / 膵臓β細胞 |
|---|
| Research Abstract |
We have focused on the physiological and functional regulation mechanism of a glycosyltransferase "GnT-IVa", modulating the glucose sensor function of pancreatic beta cells, for developing a novel antidiabetic drug. We have revealed that high fat-diet induces significant oxidative stress in pancreatic beta cells that can be a trigger to suppress GnT-IVa expression and diminishes glucose stimulated insulin secretion in the pathogenesis of type 2 diabetes. Besides, we engineered to express GnT-IVa in pancreatic beta cells in vivo, and then revealed that they are resistant to the high fat-diet induced diabetes that strongly suggest that GnT-IVa is an important target to develop antidiabetic drugs. We established cell-based assay system for exploring the drug compounds enhancing GnT-IVa expression from chemical libraries.
|
